ReviewClinical ophthalmology (Auckland, N.Z.)2023
Polypoidal Choroidal Vasculopathy: An Update on Diagnosis and Treatment.
Review in Clinical ophthalmology (Auckland, N.Z.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Choroidal vascularity index is independent of ocular and image-based factors in healthy eyes: a systematic review and meta-analysis.Scientific reports · 2025Pooled it
- Aflibercept 8 mg in Polypoidal Choroidal Vasculopathy: Post Hoc Analysis of the PULSAR Randomized Clinical Trial.JAMA ophthalmology · 2026Trial
- Clinical efficacy of conbercept combined with micropulse laser in patients with polypoidal choroidal vasculopathy.Lasers in medical science · 2025Trial
- Beyond Typical AMD: A Vodcast Exploring the Clinical and Therapeutic Landscape of PCV.Advances in therapy · 2026Article
- Long-Term Management of Polypoidal Choroidal Vasculopathy: A Narrative Review.Ophthalmology and therapy · 2026Review
- The Short-Term Outcomes of Intravitreal Faricimab for Treatment-Naïve and -Refractory Neovascular Age-Related Macular Degeneration: A Real-World Study.Medicina (Kaunas, Lithuania) · 2026Article
- Risk of intraocular hemorrhage among exudative age-related macular degeneration patients treated with different anti-VEGF agents.PloS one · 2026Article
- Subthreshold micropulse laser for retinal pigment epithelium detachment: subtype-stratified outcomes and predictors of treatment response.Frontiers in medicine · 2026Article
- Management of polypoidal choroidal vasculopathy: Malaysian Consensus Guideline 2023.International journal of ophthalmology · 2026Article
- Pachychoroid diseases of the macula: an update.Medical hypothesis, discovery & innovation ophthalmology journal · 2026Review
- Peripheral exudative hemorrhagic chorioretinopathy as a variant of polypoidal choroidal vasculopathy in a case series of Chinese patients.International journal of ophthalmology · 2026Article
- Blue Light and Green Light Fundus Autofluorescence, Complementary to Optical Coherence Tomography, in Age-Related Macular Degeneration Evaluation.Diagnostics (Basel, Switzerland) · 2025Review
- Comparative efficacy of conbercept 3+PRN versus 3+TAE regimens for the treatment of polypoidal choroidal vasculopathy.International ophthalmology · 2025Article
- Development and validation of optical coherence tomography (OCT) and OCT angiography prediction model for short-term vitreous haemorrhage secondary to polypoidal choroidal vasculopathy.The British journal of ophthalmology · 2025Article
- Switching to Faricimab for Polypoidal Choroidal Vasculopathy with Real-World Outcomes in Refractory Cases - The FAR-PEARL Study Report 1.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- Efficacy and Safety of Ophthalmic Steroids in the Management of Polypoidal Choroidal Vasculopathy: A Systematic Review.Clinical ophthalmology (Auckland, N.Z.) · 2025Review
- Blue light-emitting diode phototherapy presentsFrontiers in immunology · 2025Article
- Full-Thickness Macular Hole Formation After Intravitreal Faricimab Injection for Polypoidal Choroidal Vasculopathy.International medical case reports journal · 2025Article
- Predict and Protect: Evaluating the Double-Layer Sign in Age-Related Macular Degeneration.Ophthalmology and therapy · 2024Article
- Detection and Elimination of Senescent Cells with a Self-Assembled Senescence-Associated β-Galactosidase-Activatable Nanophotosensitizer.Journal of medicinal chemistry · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polypoidal choroidal vasculopathy (PCV) is a vascular disease of the choroid that leads to hemorrhagic and exudative macular degeneration. It may cause significant vision loss and thus affect the quality-of-life and psychological well-being. Non-invasive, non-ICGA-based OCT criteria have shown reliable results to plan adjunct photodynamic therapy (PDT) treatment, with the complete and consistent coverage of polypoidal lesions (PL) and branching neovascular network (BNN). The safety and efficacy of anti-vascular endothelial growth factor (anti-VEGF) monotherapy and its combination with verteporfin PDT have been established. However, treatment is still challenging due to frequent follow-ups, non-availability of PDT, and need for multiple anti-VEGF injection visits that increase the treatment burden and lead to patients being lost to follow-up. Effective treatments that prolong intervals between injections while maintaining vision and anatomical gains remain a critical unmet need. Longer acting molecules, like brolucizumab, have shown non-inferiority in BCVA gains and superior anatomical outcomes compared to other anti-VEGF agents. Newer therapies in the pipeline to enhance the efficacy and longevity of treatment include Faricimab and a port delivery system (PDS). This review summarizes the most recent diagnostic and treatment approaches in PCV to offer better treatment avenues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.